MedTrace Logo

The Role of Periodic Health Examination in Determining Indirect Muscle Injury Risk in Elite Football (Soccer)

NCT03782389 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 321

Last updated 2018-12-20

No results posted yet for this study

Summary

Preseason periodic health examination (PHE) is used routinely in elite football (soccer) and can be used to inform injury prevention strategies. Indirect muscle injuries (IMI) are a considerable burden to elite teams. This investigation aims to evaluate whether measurements from PHE can be used in a multivariable model to predict IMI risk in elite players, or to establish prognostic factors that are associated with IMIs.

Conditions

  • Muscle Injury
  • Sprains and Strains

Interventions

OTHER

Preseason Periodic Health Examination Completion

all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.

Sponsors & Collaborators

  • University of Manchester

    collaborator OTHER

  • Keele University

    collaborator OTHER

  • Manchester Metropolitan University

    collaborator OTHER

  • Manchester United Football Club

    lead OTHER

Principal Investigators

  • Richard Riley, PhD · Centre for Prognosis Research, Keele University. UK

  • Jamie Sergeant, PhD · Arthritis Research UK Centre for Epidemiology, University of Manchester. UK.

  • Michael Callaghan, PhD · Dept of Health Professions, Manchester Metropolitan University. UK

Eligibility

Min Age
16 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-01
Primary Completion
2018-05-19
Completion
2018-05-19

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03782389 on ClinicalTrials.gov